0001104659-23-011768.txt : 20230207 0001104659-23-011768.hdr.sgml : 20230207 20230207163058 ACCESSION NUMBER: 0001104659-23-011768 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230207 DATE AS OF CHANGE: 20230207 GROUP MEMBERS: DOUGLAS L. BRAUNSTEIN GROUP MEMBERS: HEC MANAGEMENT GP LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Akoya Biosciences, Inc. CENTRAL INDEX KEY: 0001711933 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 475586242 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-92564 FILM NUMBER: 23595487 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE STREET 2: 6TH FLOOR CITY: MARLBOROUGH STATE: MA ZIP: 01762 BUSINESS PHONE: 855.896.8401 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE STREET 2: 6TH FLOOR CITY: MARLBOROUGH STATE: MA ZIP: 01762 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Hudson Executive Capital LP CENTRAL INDEX KEY: 0001652522 IRS NUMBER: 472878186 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: C/O CADWALADER, WICKERSHAM & TAFT, LLP STREET 2: 200 LIBERTY STREET CITY: NEW YORK STATE: NY ZIP: 10281 BUSINESS PHONE: (212) 521-8495 MAIL ADDRESS: STREET 1: C/O CADWALADER, WICKERSHAM & TAFT, LLP STREET 2: 200 LIBERTY STREET CITY: NEW YORK STATE: NY ZIP: 10281 SC 13D/A 1 tm235746d1_sc13da.htm SC 13D/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

 

Akoya Biosciences, Inc.

(Name of Issuer)

 

Common Stock, $0.00001 par value
(Title of Class of Securities)

 

00974H104
(CUSIP Number)

 

Jeremy Nierman

Hudson Executive Capital LP

c/o Cadwalader, Wickersham & Taft LLP

200 Liberty Street

New York, NY 10281

(212) 521-8495

 

Copies to:

 

Richard M. Brand

Braden McCurrach
Cadwalader, Wickersham & Taft LLP
200 Liberty Street
New York, NY 10281
 (212) 504-6000
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

February 3, 2023

(Date of Event Which Requires Filing of This Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

  

CUSIP No. 00974H104 SCHEDULE 13D  

 

1

NAMES OF REPORTING PERSON

 Hudson Executive Capital LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)¨ (b) ¨

3

SEC USE ONLY

 

4

SOURCE OF FUNDS

OO

5

CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

¨

6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

1,892,204

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

1,892,204

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,892,204

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

¨

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

4.99%(1)

14

TYPE OF REPORTING PERSON

PN, IA

(1) Calculated based on 37,955,857 shares of common stock, $0.00001 par value per share, of Akoya Biosciences, Inc. (the “Company”), outstanding as reported in the Company’s Quarterly Report on Form 10-Q filed by the Company on November 8, 2022.

 

 

 

 

CUSIP No. 00974H104 SCHEDULE 13D  

 

1

NAMES OF REPORTING PERSON

 HEC Management GP LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨ (b) ¨

3

SEC USE ONLY

 

4

SOURCE OF FUNDS

OO

5

CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

¨

6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

1,892,204

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

1,892,204

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,892,204

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

¨

13

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

4.99%(2)

14

 

TYPE OF REPORTING PERSON

PN, IA

(2) Calculated based on 37,955,857 shares of common stock, $0.00001 par value per share, of the Company, outstanding as reported in the Company’s Quarterly Report on Form 10-Q filed by the Company on November 8, 2022.

 

 

 

 

CUSIP No. 00974H104 SCHEDULE 13D  

 

1

NAMES OF REPORTING PERSON

 Douglas L. Braunstein

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨ (b) ¨

3

SEC USE ONLY

 

4

SOURCE OF FUNDS

OO

5

CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

¨

6

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

1,892,204

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

1,892,204

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,892,204

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

¨

13

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

4.99%(3)

14

 

TYPE OF REPORTING PERSON

IN

(3) Calculated based on 37,955,857 shares of common stock, $0.00001 par value per share, of the Company, outstanding as reported in the Company’s Quarterly Report on Form 10-Q filed by the Company on November 8, 2022.

 

 

 

 

CUSIP No. 00974H104 SCHEDULE 13D  

 

ITEM 1. SECURITY AND ISSUER

 

This Amendment No. 3 to the Schedule 13D (the “Amendment No. 3”) relates to the Schedule 13D filed on October 18, 2021 (the “Initial 13D” and, as amended and supplemented through the date of this Amendment No. 3, collectively the “Schedule 13D”), by the Reporting Persons, relating to the common stock, $0.00001 per share (the “Shares”), of Akoya Biosciences, Inc., a company organized under the laws of the State of Delaware (the “Company”). Capitalized terms used but not defined in this Amendment No. 3 shall have the meanings set forth in the Schedule 13D.

 

This Amendment No. 3 is being filed to report a decrease in the Reporting Persons’ beneficial ownership percentage due to the sale of Shares by the Reporting Persons.

 

The Reporting Persons beneficially own an aggregate of 1,892,204 Shares (the “Subject Shares”). The Subject Shares represent approximately 4.99% of the issued and outstanding Shares based on 37,955,857 Shares outstanding as reported in the Company’s Quarterly Report on Form 10-Q filed on November 8, 2022.

 

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

 

Item 3 is hereby amended and supplemented by adding the following information:

 

As of the date hereof, the Reporting Persons are deemed to beneficially own the Subject Shares as detailed in Items 1 and 5. The aggregate purchase price for the Subject Shares is $24,129,840.40 (inclusive of brokerage commissions and other costs of execution).

 

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

 

Item 5 (a), (b), (c) and (e), are hereby amended and supplemented by adding the following information:

 

(a) and (b) Information about the number and percentage of Shares beneficially owned by the Reporting Persons is set forth in Item 1, and that information is incorporated by reference herein.

 

(c) All transactions in the Shares effected during the past 60 days on behalf of an HEC Fund over which the Reporting Persons have investment discretion are set forth in Exhibit 5 attached hereto and incorporated herein by reference.

 

(e) Following the transactions described on Exhibit 5 hereto, each of the Reporting Persons ceased to be a beneficial owner of more than five percent of the Issuer’s Shares.

 

 

 

 

CUSIP No. 00974H104 SCHEDULE 13D  

 

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

 

Item 7 is hereby amended and supplemented by adding a reference to the following exhibit:

 

Exhibit 5 Schedule of transactions effected during the last 60 days

 

 

 

 

CUSIP No. 00974H104 SCHEDULE 13D  

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 7, 2023

 

  HUDSON EXECUTIVE CAPITAL LP
   
  By:  HEC Management GP LLC, its general partner
     
  By: /s/ Douglas L. Braunstein
    Name: Douglas L. Braunstein
    Title: Managing Member

 

  HEC MANAGEMENT GP LLC
     
  By: /s/ Douglas L. Braunstein
    Name: Douglas L. Braunstein
    Title: Managing Member

 

  DOUGLAS L. BRAUNSTEIN
     
  By: /s/ Douglas L. Braunstein
    Douglas L. Braunstein

 

 

 

  

EXHIBIT 5

 

Schedule of Transactions in Shares

 

The following table sets forth all transactions with respect to Shares effected in the last sixty days by the Reporting Persons or on behalf of the Reporting Persons in respect of the Shares, inclusive of any transactions effected through 4:00 pm, New York City time, on February 7, 2023.

 

Trade Date  Transaction  Security  Quantity
Bought
(Sold)
   Unit Cost(1) 
12/5/22  Sell  Common Stock   (162,000)  $12.35(2)
12/13/22  Sell  Common Stock   (71,050)  $13.03
1/11/23  Sell  Common Stock   (2,759)  $10.85(3)
1/17/23  Sell  Common Stock   (12,000)  $10.89(4)
1/18/23  Sell  Common Stock   (13,447)  $10.73(5)
1/20/23  Sell  Common Stock   (46,209)  $10.53(6)
1/23/23  Sell  Common Stock   (55,585)  $10.58(7)
2/3/23  Sell  Common Stock   (97,530)  $12.10(8)
2/6/23  Sell  Common Stock   (94,774)  $12.20(9)

 

(1)Excludes brokerage commissions and other costs of execution.

(2)The price reported is a weighted average price. These shares were bought in transactions through a broker-dealer at prices ranging from $12.35 to $12.37, inclusive. Hudson Executive and the other Reporting Persons undertake to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote 2.

(3)The price reported is a weighted average price. These shares were bought in transactions through a broker-dealer at prices ranging from $10.83 to $10.91, inclusive. Hudson Executive and the other Reporting Persons undertake to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote 3.
(4)The price reported is a weighted average price. These shares were bought in transactions through a broker-dealer at prices ranging from $10.85 to $11.04, inclusive. Hudson Executive and the other Reporting Persons undertake to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote 4.
(5)The price reported is a weighted average price. These shares were bought in transactions through a broker-dealer at prices ranging from $10.70 to $10.77, inclusive. Hudson Executive and the other Reporting Persons undertake to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote 5.
(6)The price reported is a weighted average price. These shares were bought in transactions through a broker-dealer at prices ranging from $10.50 to $10.85, inclusive. Hudson Executive and the other Reporting Persons undertake to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote 6.
(7)The price reported is a weighted average price. These shares were bought in transactions through a broker-dealer at prices ranging from $10.50 to $10.80, inclusive. Hudson Executive and the other Reporting Persons undertake to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote 7.
(8)The price reported is a weighted average price. These shares were bought in transactions through a broker-dealer at prices ranging from $11.95 to $12.40, inclusive. Hudson Executive and the other Reporting Persons undertake to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote 8.
(9)The price reported is a weighted average price. These shares were bought in transactions through a broker-dealer at prices ranging from $11.75 to $12.49, inclusive. Hudson Executive and the other Reporting Persons undertake to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote 9.